JAK1 and rheumatoid arthritis: Baricitinib (Olumiant), a JAK1/2 inhibitor (half maximal inhibitory concentration [IC50] values of 5.9 and 5.7 nM, respectively), has been initially identified by Incyte and subsequently developed by Eli Lilly and Company for RA.